Epigenetics, microRNA, and addiction

Dialogues in Clinical Neuroscience

Volumn 16, Issue 3, 2014, Pages 335-344

  Kenny, Paul J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Amphetamine; BDNF; Cocaine; MeCP2; miR 212; Nicotine; Opiate

Indexed keywords

COCAINE; MICRORNA; MICRORNA 212; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALCOHOL CONSUMPTION; ARTICLE; BRAIN FUNCTION; COCAINE DEPENDENCE; CORPUS STRIATUM; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; MOLECULAR INTERACTION; MOTIVATION; NERVE CELL PLASTICITY; NONHUMAN; REWARD; RNA DEGRADATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; ADDICTION; ANIMAL; BRAIN; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; SUBSTANCE-RELATED DISORDERS;

EID: 84911375406     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (137)

1. Wright D, Sathe N. State Estimates of Substance Use from the 2002-2003 National Surveys on Drug Use and Health (DHHS Publication No. SMA 05-3989, NSDUH Series H-26). Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2005.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014;76 Pt B:259-268.
4. Wikler A. A psychodynamic study of a patient during experimental self-regulated re-addiction to morphine. Psychiatr Q. 1952;26:270-293.
5. Ahmed SH, Koob GF. Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology (Berl). 2005;180:473-490.
6. Ahmed SH. Imbalance between drug and non-drug reward availability: a major risk factor for addiction. Eur J Pharmacol. 2005;526:9-20.
7. Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change in hedonic set point. Science. 1998;282:298-300.
8. Kenny PJ. Brain reward systems and compulsive drug use. Trends Pharmacol Sci. 2007;28:135-141.
9. Gawin FH, Ellinwood EH, Jr. Cocaine dependence. Annu Rev Med. 1989;40:149-161.
10. Kramer JC, Fischman VS, Littlefield DC. Amphetamine abuse. Pattern and effects of high doses taken intravenously. JAMA. 1967;201:305-309.
11. Ahmed SH, Kenny PJ, Koob GF, Markou A. Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci. 2002;5:625-626.
12. Siegel RK. Changing patterns of cocaine use: longitudinal observations, consequences, and treatment. NIDA Res Monogr. 1984;50:92-110.
13. Ferri CP, Gossop M, Laranjeira RR. High dose cocaine use in Sao Paulo: a comparison of treatment and community samples. Subst Use Misuse. 2001;36:237-255.
14. Vanderschuren LJ, Everitt BJ. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science. 2004;305:1017-1019.
15. Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addiction-like behavior in the rat. Science. 2004;305:1014-1017.
16. Ahmed SH, Walker JR, Koob GF. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology. 2000;22:413-421.
17. George O, Ghozland S, Azar MR, et al. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci U S A. 2007;104:17198-17203.
18. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L. Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl). 2006;186:48-53.
19. Koob GF, Ahmed SH, Boutrel B, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;27:739-749.
20. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379:606-612.
21. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the «shell» as compared with the «core» of the rat nucleus accumbens. Proc Natl Acad Sci U S A. 1995;92:12304-12308.
22. Gonon F. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J Neurosci. 1997;17:5972-5978.
23. Ikemoto S. Involvement of the olfactory tubercle in cocaine reward: intracranial self-administration studies. J Neurosci. 2003;23:9305-9311.
24. Barak Caine S, Heinrichs SC, Coffin VL, Koob GF. Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res. 1995;692:47-56.
25. Suto N, Wise RA. Satiating effects of cocaine are controlled by dopamine actions in the nucleus accumbens core. J Neurosci. 2011;31:17917-22.
26. Suto N, Ecke L, Wise R. Control of within-binge cocaine-seeking by dopamine and glutamate in the core of nucleus accumbens. Psychopharmacology. 2009;205:431-439.
27. Ito R, Robbins TW, Everitt BJ. Differential control over cocaine-seeking behavior by nucleus accumbens core and shell. Nat Neurosci. 2004;7:389- 397.
28. Fuchs RA, Evans KA, Parker MC, See RE. Differential involvement of the core and shell subregions of the nucleus accumbens in conditioned cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology. 2004;176:459-465.
29. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274-5278.
30. Vanderschuren LJMJ, Di Ciano P, Everitt BJ. Involvement of the dorsal striatum in cue-controlled cocaine seeking. J Neurosci. 2005;25:8665-8670.
31. Zapata A, Minney VL, Shippenberg TS. Shift from goal-directed to habitual cocaine seeking after prolonged experience in rats. J Neurosci. 2010;30:15457-15463.
32. Jonkman S, Pelloux Y, Everitt BJ. Differential roles of the dorsolateral and midlateral striatum in punished cocaine seeking. J Neurosci. 2012;32:4645-4650.
33. Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry. 2007;64:1313-1320.
34. Gillespie NA, Kendler KS, Prescott CA, et al. Longitudinal modeling of genetic and environmental influences on self-reported availability of psychoactive substances: alcohol, cigarettes, marijuana, cocaine and stimulants. Psychol Med. 2007;37:947-959.
35. Guze SB, Cloninger CR, Martin R, Clayton PJ. Alcoholism as a mental disorder. Compr Psychiatry. 1986;27:501-510.
36. Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry. 1998;55:973-979.
37. Goodwin DW, Schulsinger F, Knop J, Mednick S, Guze SB. Psychopathology in adopted and nonadopted daughters of alcoholics. Arch Gen Psychiatry. 1977;34:1005-1009.
38. Goodwin DW, Schulsinger F, Moller N, Hermansen L, Winokur G, Guze SB. Drinking problems in adopted and nonadopted sons of alcoholics. Arch Gen Psychiatry. 1974;31:164-169.
39. Uhl GR, Elmer GI, Labuda MC, Pickens RW. Genetic influences in drug abuse. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York, NY: Raven Press; 1995:1793- 2783.
40. Uhl GR, Drgon T, Johnson C, et al. "Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol. 2008;75:98-111.
41. Ball D. Addiction science and its genetics. Addiction. 2008;103:360-367.
42. Nader MA, Czoty PW. PET imaging of dopamine D2 receptors in monkey models of cocaine abuse: genetic predisposition versus environmental modulation. Am J Psychiatry. 2005;162:1473-1482.
43. Impey S. A histone deacetylase regulates addiction. Neuron. 2007;56:415-417.
44. Kumar A, Choi KH, Renthal W, et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron. 2005;48:303-314.
45. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry. 2005;162:1414-1422.
46. Jones S, Bonci A. Synaptic plasticity and drug addiction. Curr Opin Pharmacol. 2005;5:20-25.
47. Kalivas PW. How do we determine which drug-induced neuroplastic changes are important? Nat Neurosci. 2005;8:1440-1441.
48. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008;33:166-180.
49. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci. 2007;8:844-858.
50. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005;8:1442-1444.
51. Lu L, Koya E, Zhai H, Hope BT, Shaham Y. Role of ERK in cocaine addiction. Trends Neurosci. 2006;29:695-703.
52. McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ. DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res. 2004;132:146-154.
53. Moghaddam B, Homayoun H. Divergent plasticity of prefrontal cortex networks. Neuropsychopharmacology. 2008;33:42-55.
54. Mulholland PJ, Chandler LJ. The thorny side of addiction: adaptive plasticity and dendritic spines. ScientificWorldJournal. 2007;7:9-21.
55. Volman SF. Evaluating the functional importance of neuroadaptions in addiction. ScientificWorldJournal. 2007;7:4-8.
56. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274-5278.
57. Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron. 2007;56:517-529.
58. Chen J, Nye HE, Kelz MB, et al. Regulation of delta FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol Pharmacol. 1995;48:880-889.
59. Hope BT, Nye HE, Kelz MB, et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 1994;13:1235-1244.
60. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci. 2003;23:742-747.
61. Benavides DR, Quinn JJ, Zhong P, et al. Cdk5 modulates cocaine reward, motivation, and striatal neuron excitability. J Neurosci. 2007;27:12967-12976.
62. Taylor JR, Lynch WJ, Sanchez H, Olausson P, Nestler EJ, Bibb JA. Inhibition of Cdk5 in the nucleus accumbens enhances the locomotor-activating and incentive-motivational effects of cocaine. Proc Natl Acad Sci U S A. 2007;104:4147-4152.
63. Covington HE, 3rd, Maze I, Sun H, et al. A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron. 2011;71:656-670.
64. Kennedy PJ, Feng J, Robison AJ, et al. Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation. Nat Neurosci. 2013;16:434-440.
65. LaPlant Q, Vialou V, Covington HE, 3rd, et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci. 2010;13:1137-1143.
66. Maze I, Covington HE, 3rd, Dietz DM, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science. 2010;327:213-216.
67. Maze I, Feng J, Wilkinson MB, Sun H, Shen L, Nestler EJ. Cocaine dynamically regulates heterochromatin and repetitive element unsilencing in nucleus accumbens. Proc Natl Acad Sci U S A. 2011;108:3035-3040.
68. Lai EC. microRNAs: runts of the genome assert themselves. Curr Biol. 2003;13:R925-R936.
69. Lai EC. miRNAs: whys and wherefores of miRNA-mediated regulation. Curr Biol. 2005;15:R458-R460.
70. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science. 2003;299:1540.
71. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901-906.
72. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001;294:858-862.
73. Ruby JG, Jan C, Player C, et al. Large-scale sequencing reveals 21URNAs and additional microRNAs and endogenous siRNAs in C. elegans. Cell. 2006;127:1193-1207.
74. Rajagopalan R, Vaucheret H, Trejo J, Bartel DP. A diverse and evolutionarily fluid set of microRNAs in Arabidopsis thaliana. Genes Dev. 2006;20:3407-3425.
75. Jones-Rhoades MW, Bartel DP, Bartel B. MicroRNAS and their regulatory roles in plants. Annu Rev Plant Biol. 2006;57:19-53.
76. Axtell MJ, Bartel DP. Antiquity of microRNAs and their targets in land plants. Plant Cell. 2005;17:1658-1673.
77. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. Rna. 2003;9:1274-1281.
78. Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004;5:R68.
79. Giraldez AJ, Cinalli RM, Glasner ME, et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science. 2005;308:833-838.
80. Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH, Wilson SW. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol. 2007;8:R173.
81. Bilen J, Liu N, Bonini NM. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle. 2006;5:2835-2838.
82. Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell. 2007;131:136-145.
83. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR- 124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell. 2007;27:435-448.
84. Schaefer A, O'Carroll D, Tan CL, et al. Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med. 2007;204:1553-1558.
85. Kye MJ, Liu T, Levy SF, et al. Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. Rna. 2007;13:1224-1234.
86. Kiebler MA, DesGroseillers L. Molecular insights into mRNA transport and local translation in the mammalian nervous system. Neuron. 2000;25:19-28.
87. Ashraf SI, McLoon AL, Sclarsic SM, Kunes S. Synaptic protein synthesis associated with memory is regulated by the RISC pathway in Drosophila. Cell. 2006;124:191-205.
88. Duan R, Jin P. Identification of messenger RNAs and microRNAs associated with fragile X mental retardation protein. Methods Mol Biol. 2006;342:267-276.
89. Plante I, Davidovic L, Ouellet DL, et al. Dicer-derived MicroRNAs are utilized by the fragile X mental retardation protein for assembly on target RNAs. J Biomed Biotechnol. 2006;2006:643647.
90. Zalfa F, Bagni C. Another view of the role of FMRP in translational regulation. Cell Mol Life Sci. 2005;62:251-252.
91. Edbauer D, Neilson JR, Foster KA, et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron. 2010;65:373-384.
92. Gong X, Zhang K, Wang Y, et al. MicroRNA-130b targets Fmr1 and regulates embryonic neural progenitor cell proliferation and differentiation. Biochem Biophys Res Commun. 2013;439:493-500.
93. Muddashetty RS, Nalavadi VC, Gross C, et al. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol Cell. 2011;42:673-688.
94. Sudhakaran IP, Hillebrand J, Dervan A, et al. FMRP and Ataxin-2 function together in long-term olfactory habituation and neuronal translational control. Proc Natl Acad Sci U S A. 2014;111:E99-E108.
95. Xu XL, Zong R, Li Z, et al. FXR1P but not FMRP regulates the levels of mammalian brain-specific microRNA-9 and microRNA-124. J Neurosci. 2011;31:13705-13709.
96. Ashraf SI, Kunes S. A trace of silence: memory and microRNA at the synapse. Curr Opin Neurobiol. 2006;16:535-539.
97. Gao J, Wang WY, Mao YW, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010;466:1105-1109.
98. Lin Q, Wei W, Coelho CM, Li X, et al. The brain-specific microRNA miR-128b regulates the formation of fear-extinction memory. Nat Neurosci. 2011;14:1115-1117.
99. McNeill E, Van Vactor D. MicroRNAs shape the neuronal landscape. Neuron. 2012;75:363-379.
100. Mellios N, Sugihara H, Castro J, et al. miR-132, an experience-dependent microRNA, is essential for visual cortex plasticity. Nat Neurosci. 2011;14:1240-1242.
101. Sim SE, Bakes J, Kaang BK. Neuronal activity-dependent regulation of MicroRNAs. Mol Cell. 2014;37:511-517.
102. Sosanya NM, Huang PP, Cacheaux LP, et al. Degradation of high affinity HuD targets releases Kv1.1 mRNA from miR-129 repression by mTORC1. J Cell Biol. 2013;202:53-69.
103. Vetere G, Barbato C, Pezzola S, et al. Selective inhibition of miR-92 in hippocampal neurons alters contextual fear memory. Hippocampus. In press.
104. Kenny PJ, Voren G, Johnson PM. Dopamine D2 receptors and striatopallidal transmission in addiction and obesity. Curr Opin Neurobiol. 2013;23:535-538.
105. Schaefer A, Im HI, Veno MT, et al. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J Exp Med. 2010;207:1843-1851.
106. Eipper-Mains JE, Kiraly DD, Palakodeti D, Mains RE, Eipper BA, Graveley BR. microRNA-Seq reveals cocaine-regulated expression of striatal microRNAs. RNA. 2011;17:1529-1543.
107. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012;35:325-334.
108. Jonkman S, Kenny PJ. Molecular, cellular, and structural mechanisms of cocaine addiction: a key role for microRNAs. Neuropsychopharmacology. 2013;38:198-211.
109. Li MD, van der Vaart AD. MicroRNAs in addiction: adaptation's middlemen? Mol Psychiatry. 2011;16:1159-1168.
110. Pietrzykowski AZ. The role of microRNAs in drug addiction: a big lesson from tiny molecules. Int Rev Neurobiol. 2010;91:1-24.
111. Rodriguez RE. Morphine and microRNA activity: is there a relation with addiction? Front Genet. 2012;3:223.
112. Sartor GC, St Laurent G, 3rd, Wahlestedt C. The emerging role of noncoding RNAs in drug addiction. Front Genet. 2012;3:106.
113. Chandrasekar V, Dreyer JL. microRNAs miR-124, let-7d and miR- 181a regulate cocaine-induced plasticity. Mol Cell Neurosci. 2009;42:350- 362.
114. Chandrasekar V, Dreyer JL. Regulation of MiR-124, Let-7d, and MiR- 181a in the accumbens affects the expression, extinction, and reinstatement of cocaine-induced conditioned place preference. Neuropsychopharmacology. 2011;36:1149-1164.
115. Hollander JA, Im H-I, Amelio AL, et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature. 2010;466:197-202.
116. Vo N, Klein ME, Varlamova O, et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A. 2005;102:16426-16431.
117. Wayman GA, Davare M, Ando H, et al. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci U S A. 2008;105:9093-9098.
118. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Molecular Cell. 2007;26:753-767.
119. Carlezon WA, Jr, Thome J, Olson VG, et al. Regulation of cocaine reward by CREB. Science. 1998;282:2272-2275.
120. Dinieri JA, Nemeth CL, Parsegian A, et al. Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci. 2009;29:1855-1859.
121. McClung CA, Nestler EJ. Regulation of gene expression and cocaine reward by CREB and [Delta]FosB. Nat Neurosci. 2003;6:1208-1215.
122. Varga EV, Rubenzik M, Grife V, et al. Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. Eur J Pharmacol. 2002;451:101-102.
123. Bahi A, Dreyer JL. Striatal modulation of BDNF expression using microRNA124a-expressing lentiviral vectors impairs ethanol-induced conditioned-place preference and voluntary alcohol consumption. Eur J Neurosci. 2013;38:2328-2337.
124. Li J, Li J, Liu X, et al. MicroRNA expression profile and functional analysis reveal that miR-382 is a critical novel gene of alcohol addiction. EMBO Mol Med. 2013;5:1402-1414.
125. Nestler EJ. Review. Transcriptional mechanisms of addiction: role of DeltaFosB. Philos Trans R Soc Lond B Biol Sci. 2008;363:3245-3255.
126. Tapocik JD, Barbier E, Flanigan M, et al. microRNA-206 in rat medial prefrontal cortex regulates BDNF expression and alcohol drinking. J Neurosci. 2014;34:4581-4588.
127. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol. 2010;42:1252-1255.
128. Tian N, Cao Z, Zhang Y. MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer's disease. Neurosci Bull. 2014;30:191-197.
129. Radzikinas K, Aven L, Jiang Z, et al. A Shh/miR-206/BDNF cascade coordinates innervation and formation of airway smooth muscle. J Neurosci. 2011;31:15407-15415.
130. Miura P, Amirouche A, Clow C, Belanger G, Jasmin BJ. Brain-derived neurotrophic factor expression is repressed during myogenic differentiation by miR-206. J Neurochem. 2012;120:230-238.
131. Lee ST, Chu K, Jung KH, et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol. 2012;72:269- 277.
132. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64:238-258.
133. Acar M, Becskei A, van Oudenaarden A. Enhancement of cellular memory by reducing stochastic transitions. Nature. 2005;435:228-232.
134. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2. Nat Genet. 1999;23:185-188.
135. Van Esch H, Bauters M, Ignatius J, et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet. 2005;77:442-53.
136. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386-389.
137. Im H-I, Hollander JA, Bali P, Kenny PJ. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci. 2010;13:1120-1127.